Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 2Ovarian Neoplasms 1

Interventions

Paclitaxel 42Carboplatin 35pembrolizumab 25Surveys and Questionnaires 23Letrozole 15Radiotherapy 14Megestrol Acetate 14Blood Specimen Collection 14Bevacizumab 13olaparib 12Metformin 12dostarlimab 10Indocyanine Green 10durvalumab 9Observation 9Medroxyprogesterone Acetate 9Cisplatin 9lenvatinib 8atezolizumab 8Early Intervention, Educational 8Counseling 8niraparib 7Sentinel Lymph Node Biopsy 7Radiation 7Methods 7Magnetic Resonance Spectroscopy 7Lymph Node Excision 7Hysterectomy 7Everolimus 7abemaciclib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Endometrial Neoplasms × LY3023414 × Clear all
NCT03675893 2025-06-15

RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer

Dana-Farber Cancer Institute

Phase 2 Recruiting
180 enrolled
Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT02549989 2023-02-22

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
28 enrolled 12 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡